Collaboration and Licensing Revenue (Tables)

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the three and nine months ended September 30, 2016 and 2015.

	Three Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	4,843	$	5,586	$	10,429
Oragenics, Inc.	262		294		556
Fibrocell Science, Inc.	604		563		1,167
Genopaver, LLC	68		1,625		1,693
S & I Ophthalmic, LLC	—		2,782		2,782
OvaXon, LLC	—		709		709
Intrexon Energy Partners, LLC	625		4,230		4,855
Persea Bio, LLC	125		208		333
Ares Trading S.A.	1,597		719		2,316
Thrive Agrobiotics, Inc.	46		379		425
Intrexon Energy Partners II, LLC	500		372		872
Exotech Bio, Inc.	139		82		221
Relieve Genetics, Inc.	120		342		462
Intrexon T1D Partners, LLC	276		511		787
AD Skincare, Inc.	120		65		185
Other	895		1,903		2,798
Total	$	10,220	$	20,370	$	30,590

	Three Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	645	$	4,006	$	4,651
Oragenics, Inc.	4,868		332		5,200
Fibrocell Science, Inc.	4,823		1,317		6,140
Genopaver, LLC	68		993		1,061
S & I Ophthalmic, LLC	—		1,193		1,193
OvaXon, LLC	—		549		549
Intrexon Energy Partners, LLC	625		3,185		3,810
Persea Bio, LLC	125		297		422
Ares Trading S.A.	1,597		260		1,857
Other	7,841		2,002		9,843
Total	$	20,592	$	14,134	$	34,726

	Nine Months Ended September 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	6,687	$	17,693	$	24,380
Oragenics, Inc.	786		1,083		1,869
Fibrocell Science, Inc.	1,814		2,604		4,418
Genopaver, LLC	205		4,703		4,908
S & I Ophthalmic, LLC	—		6,326		6,326
OvaXon, LLC	—		2,211		2,211
Intrexon Energy Partners, LLC	1,875		11,180		13,055
Persea Bio, LLC	375		613		988
Ares Trading S.A.	4,791		2,148		6,939
Thrive Agrobiotics, Inc.	138		1,171		1,309
Intrexon Energy Partners II, LLC	1,500		816		2,316
Exotech Bio, Inc.	278		82		360
Relieve Genetics, Inc.	240		572		812
Intrexon T1D Partners, LLC	554		543		1,097
AD Skincare, Inc.	120		65		185
Other	4,684		6,287		10,971
Total	$	24,047	$	58,097	$	82,144

	Nine Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,933	$	11,769	$	13,702
Oragenics, Inc.	5,437		408		5,845
Fibrocell Science, Inc.	5,719		4,500		10,219
Genopaver, LLC	205		2,460		2,665
S & I Ophthalmic, LLC	—		2,838		2,838
OvaXon, LLC	—		1,855		1,855
Intrexon Energy Partners, LLC	1,875		8,101		9,976
Persea Bio, LLC	375		553		928
Ares Trading S.A.	2,336		260		2,596
Other	9,446		6,620		16,066
Total	$	27,326	$	39,364	$	66,690

Summary of Deferred Revenue

Deferred revenue consists of the following:

	September 30, 2016		December 31, 2015
Upfront and milestone payments	$	309,126	$	181,331
Prepaid research and development services	7,057		10,938
Prepaid product and service revenues	5,594		4,759
Other	620		701
Total	$	322,397	$	197,729
Current portion of deferred revenue	$	54,937	$	35,366
Long-term portion of deferred revenue	267,460		162,363
Total	$	322,397	$	197,729

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:

	September 30, 2016		December 31, 2015
ZIOPHARM Oncology, Inc.	$	143,651	$	30,338
Oragenics, Inc.	8,027		8,813
Fibrocell Science, Inc.	19,631		21,445
Genopaver, LLC	2,045		2,250
Intrexon Energy Partners, LLC	18,750		20,625
Persea Bio, LLC	4,125		4,500
Ares Trading S.A.	48,776		53,567
Thrive Agrobiotics, Inc.	1,483		1,621
Intrexon Energy Partners II, LLC	16,333		17,833
Exotech Bio, Inc.	4,722		—
Relieve Genetics, Inc.	4,093		—
Intrexon T1D Partners, LLC	9,383		—
AD Skincare, Inc.	4,213		—
Genten Therapeutics, Inc.	4,523		—
CRS Bio, Inc.	2,111		—
Other	17,260		20,339
Total	$	309,126	$	181,331